This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092

Slideshow ProjectDOI:10.1682/JRRD.2013.04.0092JSP

Proposed comprehensive ototoxicity monitoring program for VA

healthcare (COMP-VA)

Dawn Konrad-Martin, PhD; Kelly M. Reavis, MPH; Garnett McMillan, PhD; Wendy J. Helt, MA; Marilyn Dille, PhD

This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092

Slideshow ProjectDOI:10.1682/JRRD.2013.04.0092JSP

• Aim– Describe COMP-VA, a comprehensive ototoxicity

monitoring program developed for VA patients receiving cisplatin.

• Relevance– With improved survivability following cancer

treatment, Veterans treated with cisplatin have dual goals of effective treatment and preserved quality of life.

This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092

Slideshow ProjectDOI:10.1682/JRRD.2013.04.0092JSP

Method• COMP-VA is designed to be

administered on chemo-therapy treatment unit just before treatment (chairside). – Uses portable ototoxicity

identification device (OtoID) that can provide reliable and accurate hearing thresholds on hospital ward during treatment.

This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092

Slideshow ProjectDOI:10.1682/JRRD.2013.04.0092JSP

Clinical Objectives• Pretreatment ototoxicity risk assessment.• Behavioral screening for early hearing changes.• Screening for outer hair cell dysfunction.• Nonbehavioral screening for early hearing changes.• Screen failure follow-up testing.• Screening for tinnitus.• Patient and provider education about ototoxic-induced

hearing and tinnitus, synergistic effects of ototoxins and noise overexposure, and rehabilitative solutions to hearing loss and tinnitus.

This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092

Slideshow ProjectDOI:10.1682/JRRD.2013.04.0092JSP

Conclusion

• Using evidence-based behavioral and objective test protocols, COMP-VA provides up-to-the-minute estimates of ototoxicity before patient’s next treatment.– This allows for timely consideration of treatment

changes.

• Program encourages efficient communication and team relationships between audiology and oncology.